{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T16:03:29Z","timestamp":1784217809947,"version":"3.55.0"},"reference-count":79,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"abstract":"<jats:p>Background: Malignant pleural mesothelioma (MPM) is a rare thoracic malignancy with poor prognosis and limited treatment options. Immunotherapy shows potential for improved outcomes; however, real-world evidence on its use will take time to accumulate. This study examined patient characteristics, treatment patterns, overall survival (OS), and predictors of mortality among patients diagnosed with MPM in Denmark prior to the introduction of newer treatments.\nMethods: This historical cohort study based on routinely collected Danish National Registry data included adults newly diagnosed with MPM between 01 January 2011 and 31 May 2018. Summary statistics were used to describe patient characteristics and initial treatment. OS was estimated using Kaplan-Meier methods; Cox regression was used to compare patient mortality against the (age\/sex-matched) general population and to investigate mortality predictors.\nResults: Overall, 880 patients were included; 44% had advanced MPM, 37% had non-advanced MPM, and 19% had unknown MPM stage. Median age at diagnosis was 71.9 years, and 82% of the patients were male. Within 180 days of diagnosis, no treatment was recorded for 215 patients (54%) with advanced MPM and 150 (46%) with non-advanced MPM. Median time-to-initial treatment (interquartile range) was 47 days (31\u2013111) overall, 40 days (28\u201377) in patients with advanced MPM, and 53 days (35\u2013121) with non-advanced MPM. Median OS was 13.7 months overall (non-advanced MPM: 18.0 months vs. advanced MPM: 10.0 months). Predictors of higher mortality were older age at diagnosis, histology, and advanced MPM stage.\nInterpretation: These findings provide a baseline upon which to evaluate MPM epidemiology as newer treatments are adopted in routine practice.<\/jats:p>","DOI":"10.2340\/1651-226x.2024.34802","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T05:20:23Z","timestamp":1723094423000},"page":"649-657","source":"Crossref","is-referenced-by-count":6,"title":["Patient characteristics, treatment patterns, and survival outcomes for patients with malignant pleural mesothelioma in Denmark between 2011 and 2018: a nationwide population-based cohort study"],"prefix":"10.2340","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7780-0178","authenticated-orcid":false,"given":"Jens Benn","family":"S\u00f8rensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Baas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szimonetta Komj\u00e1thin\u00e9","family":"Sz\u00e9pligeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma B.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren P.","family":"Johnsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minouk J.","family":"Schoemaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Rault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda J.","family":"Daumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Ehrenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"key":"70387","doi-asserted-by":"crossref","unstructured":"Tedesco J, Jaradeh M, Vigneswaran WT. Malignant pleural mesothelioma: current understanding of the immune microenvironment and treatments of a rare disease. Cancers (Basel). 2022;14(18):4415.","DOI":"10.3390\/cancers14184415"},{"key":"70388","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/cancers14184415","DOI":"10.3390\/cancers14184415"},{"key":"70389","doi-asserted-by":"crossref","unstructured":"Zhai Z, Ruan J, Zheng Y, Xiang D, Li N, Hu J et al. Assessment of global trends in the diagnosis of mesothelioma from 1990 to 2017. JAMA Netw Open. 2021;4(8):e2120360.","DOI":"10.1001\/jamanetworkopen.2021.20360"},{"key":"70390","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.20360","DOI":"10.1001\/jamanetworkopen.2021.20360"},{"key":"70391","doi-asserted-by":"crossref","unstructured":"Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S et al. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v31\u2013v39.","DOI":"10.1093\/annonc\/mdv199"},{"key":"70392","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/annonc\/mdv199","DOI":"10.1093\/annonc\/mdv199"},{"key":"70393","doi-asserted-by":"crossref","unstructured":"Hemminki K, Forsti A, Chen T, Hemminki A. Incidence, mortality and survival in malignant pleural mesothelioma before and after asbestos in Denmark, Finland, Norway and Sweden. BMC Cancer. 2021;21(1):1189.","DOI":"10.1186\/s12885-021-08913-2"},{"key":"70394","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s12885-021-08913-2","DOI":"10.1186\/s12885-021-08913-2"},{"key":"70395","doi-asserted-by":"crossref","unstructured":"Scherpereel A, Opitz I, Berghmans T, Psallidas I, Glatzer M, Rigau D et al. ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020;55(6):1900953.","DOI":"10.1183\/13993003.00953-2019"},{"key":"70396","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1183\/13993003.00953-2019","DOI":"10.1183\/13993003.00953-2019"},{"key":"70397","doi-asserted-by":"crossref","unstructured":"Reid A, de Klerk NH, Magnani C, Ferrante D, Berry G, Musk AW et al. Mesothelioma risk after 40 years since first exposure to asbestos: a pooled analysis. Thorax. 2014;69(9):843\u2013850.","DOI":"10.1136\/thoraxjnl-2013-204161"},{"key":"70398","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/thoraxjnl-2013-204161","DOI":"10.1136\/thoraxjnl-2013-204161"},{"key":"70399","doi-asserted-by":"crossref","unstructured":"Fonseca AS, Jorgensen AK, Larsen BX, Moser-Johansen M, Flachs EM, Ebbehoj NE et al. Historical asbestos measurements in Denmark-a national database. Int J Environ Res Public Health. 2022;19(2):643.","DOI":"10.3390\/ijerph19020643"},{"key":"70400","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/ijerph19020643","DOI":"10.3390\/ijerph19020643"},{"key":"70401","doi-asserted-by":"crossref","unstructured":"Mensi C, De Matteis S, Dallari B, Riboldi L, Bertazzi PA, Consonni D. Incidence of mesothelioma in Lombardy, Italy: exposure to \u00adasbestos, time patterns and future projections. Occup Environ Med. 2016;73(9):607\u2013613.","DOI":"10.1136\/oemed-2016-103652"},{"key":"70402","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/oemed-2016-103652","DOI":"10.1136\/oemed-2016-103652"},{"key":"70403","doi-asserted-by":"crossref","unstructured":"Loomis D, Richardson DB, Elliott L. Quantitative relationships of exposure to chrysotile asbestos and mesothelioma mortality. Am J Ind Med. 2019;62(6):471\u2013477.","DOI":"10.1002\/ajim.22985"},{"key":"70404","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/ajim.22985","DOI":"10.1002\/ajim.22985"},{"key":"70405","doi-asserted-by":"crossref","unstructured":"Brims F. Epidemiology and clinical aspects of malignant pleural mesothelioma. Cancers (Basel). 2021;13(16):4194.","DOI":"10.3390\/cancers13164194"},{"key":"70406","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/cancers13164194","DOI":"10.3390\/cancers13164194"},{"key":"70407","doi-asserted-by":"crossref","unstructured":"Amin W, Linkov F, Landsittel DP, Silverstein JC, Bashara W, Gaudioso C et al. Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort. F1000Res. 2018;7:1184.","DOI":"10.12688\/f1000research.15512.2"},{"key":"70408","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.12688\/f1000research.15512.2","DOI":"10.12688\/f1000research.15512.2"},{"key":"70409","doi-asserted-by":"crossref","unstructured":"Bibby AC, Tsim S, Kanellakis N, Ball H, Talbot DC, Blyth KG et al. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. Eur Respir Rev. 2016;25(142):472\u2013486.","DOI":"10.1183\/16000617.0063-2016"},{"key":"70410","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1183\/16000617.0063-2016","DOI":"10.1183\/16000617.0063-2016"},{"key":"70411","unstructured":"American Cancer Society. Survival rates for malignant mesothelioma. [cited 2022 Nov 14]. Available from: https:\/\/www.cancer.org\/cancer\/malignant-mesothelioma\/detection-diagnosis-staging\/survival-statistics.html"},{"key":"70412","doi-asserted-by":"crossref","unstructured":"Offin M, Rusch VW, Rimner A, Adusumilli PS, Zauderer MG. Evolving landscape of initial treatments for patients with malignant pleural mesotheliomas: clinical trials to clinical practice. Oncologist. 2022;27(8):610\u2013614.","DOI":"10.1093\/oncolo\/oyac113"},{"key":"70413","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/oncolo\/oyac113","DOI":"10.1093\/oncolo\/oyac113"},{"key":"70414","doi-asserted-by":"crossref","unstructured":"Rusch VW, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D et al. Initial analysis of the International Association for the Study of Lung Cancer mesothelioma database. J Thorac Oncol. 2012;7(11):1631\u20131639.","DOI":"10.1097\/JTO.0b013e31826915f1"},{"key":"70415","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/JTO.0b013e31826915f1","DOI":"10.1097\/JTO.0b013e31826915f1"},{"key":"70416","doi-asserted-by":"crossref","unstructured":"Meyerhoff RR, Yang CF, Speicher PJ, Gulack BC, Hartwig MG, D\u2019Amico TA et al. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. J Surg Res. 2015;196(1):23\u201332.","DOI":"10.1016\/j.jss.2015.01.043"},{"key":"70417","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jss.2015.01.043","DOI":"10.1016\/j.jss.2015.01.043"},{"key":"70418","doi-asserted-by":"crossref","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636\u20132644.","DOI":"10.1200\/JCO.2003.11.136"},{"key":"70419","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.2003.11.136","DOI":"10.1200\/JCO.2003.11.136"},{"key":"70420","doi-asserted-by":"crossref","unstructured":"Nowak AK, Jackson A, Sidhu C. Management of advanced pleural mesothelioma-at the crossroads. JCO Oncol Pract. 2022;18(2):116\u2013124.","DOI":"10.1200\/OP.21.00426"},{"key":"70421","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/OP.21.00426","DOI":"10.1200\/OP.21.00426"},{"key":"70422","doi-asserted-by":"crossref","unstructured":"Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375\u2013386.","DOI":"10.1016\/S0140-6736(20)32714-8"},{"key":"70423","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(20)32714-8","DOI":"10.1016\/S0140-6736(20)32714-8"},{"key":"70424","unstructured":"Bristol Myers Squibb. Bristol Myers Squibb receives European Commission approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) as first-line treatment for unresectable malignant pleural mesothelioma. 2021 [cited 2022 Nov 23]. Available from: https:\/\/news.bms.com\/news\/details\/2021\/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-as-First-Line-Treatment-for-Unresectable-Malignant-Pleural-Mesothelioma\/default.aspx"},{"key":"70425","doi-asserted-by":"crossref","unstructured":"Nakajima EC, Vellanki PJ, Larkins E, Chatterjee S, Mishra-Kalyani PS, Bi Y et al. FDA approval summary: nivolumab in combination with ipilimumab for the treatment of unresectable malignant pleural mesothelioma. Clin Cancer Res. 2022;28(3):446\u2013451.","DOI":"10.1158\/1078-0432.CCR-21-1466"},{"key":"70426","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1466","DOI":"10.1158\/1078-0432.CCR-21-1466"},{"key":"70427","doi-asserted-by":"crossref","unstructured":"Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK et al. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(2):129\u2013142.","DOI":"10.1016\/j.annonc.2021.11.005"},{"key":"70428","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.annonc.2021.11.005","DOI":"10.1016\/j.annonc.2021.11.005"},{"key":"70429","unstructured":"Medicinraadet. Medicinraadet 2022. [cited 2023 May 17]. Available from: https:\/\/medicinraadet.dk\/anbefalinger-og-vejledninger\/laegemidler-og-indikationsudvidelser\/m-p\/nivolumab-opdivo-i-komb-med-ipilimumab-til-1-linjebehandling-af-ikke-resekterbar-malignt-pleuralt-mesotheliom"},{"key":"70430","doi-asserted-by":"crossref","unstructured":"Baas P, Daumont MJ, Lacoin L, Penrod JR, Carroll R, Venkatesan S et al. Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013\u20132017: a nationwide CAS registry analysis from the I-O Optimise initiative. Lung Cancer. 2021;162:185\u2013193.","DOI":"10.1016\/j.lungcan.2021.11.001"},{"key":"70431","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.11.001","DOI":"10.1016\/j.lungcan.2021.11.001"},{"key":"70432","doi-asserted-by":"crossref","unstructured":"Laugesen K, Ludvigsson JF, Schmidt M, Gissler M, Valdimarsdottir UA, Lunde A et al. Nordic health registry-based research: a review of health care systems and key registries. Clin Epidemiol. 2021;13:533\u2013554.","DOI":"10.2147\/CLEP.S314959"},{"key":"70433","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/CLEP.S314959","DOI":"10.2147\/CLEP.S314959"},{"key":"70434","doi-asserted-by":"crossref","unstructured":"Ekman S, Griesinger F, Baas P, Chao D, Chouaid C, O\u2019Donnell JC et al. I-O Optimise: a novel multinational real-world research platform in thoracic malignancies. Future Oncol. 2019;15(14):1551\u20131563.","DOI":"10.2217\/fon-2019-0025"},{"key":"70435","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2217\/fon-2019-0025","DOI":"10.2217\/fon-2019-0025"},{"key":"70436","doi-asserted-by":"crossref","unstructured":"Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541\u2013549.","DOI":"10.1007\/s10654-014-9930-3"},{"key":"70437","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s10654-014-9930-3","DOI":"10.1007\/s10654-014-9930-3"},{"key":"70438","doi-asserted-by":"crossref","unstructured":"Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health. 2011;39(7 Suppl):42\u201345.","DOI":"10.1177\/1403494810393562"},{"key":"70439","doi-asserted-by":"crossref","unstructured":"Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449\u2013490.","DOI":"10.2147\/CLEP.S91125"},{"key":"70440","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/CLEP.S91125","DOI":"10.2147\/CLEP.S91125"},{"key":"70441","doi-asserted-by":"crossref","unstructured":"Berzenji L, Van Schil PE, Carp L. The eighth TNM classification for malignant pleural mesothelioma. Transl Lung Cancer Res. 2018;7(5):543\u2013549.","DOI":"10.21037\/tlcr.2018.07.05"},{"key":"70442","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.21037\/tlcr.2018.07.05","DOI":"10.21037\/tlcr.2018.07.05"},{"key":"70443","doi-asserted-by":"crossref","unstructured":"Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer. 1996;14(1):1\u201312.","DOI":"10.1016\/0169-5002(95)00508-0"},{"key":"70444","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/0169-5002(95)00508-0","DOI":"10.1016\/0169-5002(95)00508-0"},{"key":"70445","doi-asserted-by":"crossref","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457\u2013481.","DOI":"10.1080\/01621459.1958.10501452"},{"key":"70446","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/01621459.1958.10501452","DOI":"10.1080\/01621459.1958.10501452"},{"key":"70447","doi-asserted-by":"crossref","unstructured":"Cox DR. Regression models and life-tables. J R Stat Soc Series B Stat Methodol. 1972;34:187\u2013220.","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"70448","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.2517-6161.1972.tb00899.x","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"70449","doi-asserted-by":"crossref","unstructured":"Damhuis RA, Khakwani A, De Schutter H, Rich AL, Burgers JA, van Meerbeeck JP. Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England. Lung Cancer. 2015;89(2):212\u2013217.","DOI":"10.1016\/j.lungcan.2015.05.014"},{"key":"70450","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.lungcan.2015.05.014","DOI":"10.1016\/j.lungcan.2015.05.014"},{"key":"70451","doi-asserted-by":"crossref","unstructured":"Alpert N, van Gerwen M, Taioli E. Epidemiology of mesothelioma in the 21(st) century in Europe and the United States, 40 years after restricted\/banned asbestos use. Transl Lung Cancer Res. 2020;9(Suppl 1):S28\u2013S38.","DOI":"10.21037\/tlcr.2019.11.11"},{"key":"70452","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.21037\/tlcr.2019.11.11","DOI":"10.21037\/tlcr.2019.11.11"},{"key":"70453","doi-asserted-by":"crossref","unstructured":"Brcic L, Kern I. Clinical significance of histologic subtyping of malignant pleural mesothelioma. Transl Lung Cancer Res. 2020;9(3):924\u2013933.","DOI":"10.21037\/tlcr.2020.03.38"},{"key":"70454","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.21037\/tlcr.2020.03.38","DOI":"10.21037\/tlcr.2020.03.38"},{"key":"70455","doi-asserted-by":"crossref","unstructured":"Ziolkowska B, Cybulska-Stopa B, Papantoniou D, Suwinski R. Systemic treatment in patients with malignant pleural mesothelioma \u2013 real life experience. BMC Cancer. 2022;22(1):432.","DOI":"10.1186\/s12885-022-09490-8"},{"key":"70456","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s12885-022-09490-8","DOI":"10.1186\/s12885-022-09490-8"},{"key":"70457","doi-asserted-by":"crossref","unstructured":"Kuryk L, Rodella G, Staniszewska M, Pancer KW, Wieczorek M, Salmaso S et al. Novel insights into mesothelioma therapy: emerging avenues and future prospects. Front Oncol. 2022;12:916839.","DOI":"10.3389\/fonc.2022.916839"},{"key":"70458","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fonc.2022.916839","DOI":"10.3389\/fonc.2022.916839"},{"key":"70459","unstructured":"Skammeritz E, Omland O, Hansen J, Johansen JP. Regional differences in incidence of malignant mesothelioma in Denmark. Dan Med J. 2013;60(3):A4592."},{"key":"70460","doi-asserted-by":"crossref","unstructured":"Rijavec E, Biello F, Barletta G, Dellepiane C, Genova C. Novel approaches for the treatment of unresectable malignant pleural mesothelioma: a focus on immunotherapy and target therapy (review). Mol Clin Oncol. 2022;16(4):89.","DOI":"10.3892\/mco.2022.2522"},{"key":"70461","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3892\/mco.2022.2522","DOI":"10.3892\/mco.2022.2522"},{"key":"70462","doi-asserted-by":"crossref","unstructured":"Davis AP, Kao SC, Clarke SJ, Boyer M, Pavlakis N. Emerging biological therapies for the treatment of malignant pleural mesothelioma. Expert Opin Emerg Drugs. 2021;26(2):179\u2013192.","DOI":"10.1080\/14728214.2021.1924670"},{"key":"70463","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/14728214.2021.1924670","DOI":"10.1080\/14728214.2021.1924670"},{"key":"70464","doi-asserted-by":"crossref","unstructured":"Lapidot M, Saladi SV, Salgia R, Sattler M. Novel therapeutic targets and immune dysfunction in malignant pleural mesothelioma. Front Pharmacol. 2021;12:806570.","DOI":"10.3389\/fphar.2021.806570"},{"key":"70465","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fphar.2021.806570","DOI":"10.3389\/fphar.2021.806570"}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/34802\/46854","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/34802\/46855","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/34802\/46854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T18:02:54Z","timestamp":1756404174000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/34802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":79,"URL":"https:\/\/doi.org\/10.2340\/1651-226x.2024.34802","relation":{},"ISSN":["1651-226X","0284-186X"],"issn-type":[{"value":"1651-226X","type":"electronic"},{"value":"0284-186X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,8]]}}}